肿瘤细胞治疗研究
英文原题：CAR-T/NK/M-based combination therapies in cancer: A comprehensive review.
CAR-T（CAR-T）细胞疗法与其他治疗或药物联合应用，是肿瘤免疫治疗领域的突破性进展。
CAR-T（CAR-T）细胞疗法与其他治疗或药物联合，是癌症免疫治疗领域的突破性进展。CAR-T免疫疗法取得显著发展，美国FDA已批准多种疗法用于血液系统恶性肿瘤。研究表明，CAR-NK和CAR巨噬细胞（CAR-M）疗法对实体瘤的效果优于CAR-T类疗法。CAR类疗法与免疫调节剂、细胞因子、溶瘤病毒和免疫检查点抑制剂联用具有协同潜力，为治疗多种癌症提供了有前景策略。本综述全面考察CAR-T、CAR-NK和CAR-M疗法的现状和应用，尤其关注其与免疫调节剂及其他分子联合治疗实体瘤，包括胶质母细胞瘤、胰腺癌、胃癌、肝癌、卵巢癌、肺癌和乳腺癌。
Chimeric Antigen Receptor T (CAR-T) cell therapy, in combination with other treatments or medications, presents a groundbreaking development in cancer immunotherapy. CAR-T immunotherapy has shown remarkable progress, with multiple therapies approved by the US FDA for hematological malignancies. Studies indicate that CAR-NK and CAR-M therapies are more effective against solid tumors than CAR-T-based therapy. The synergistic potential of combining CAR-based therapies with immunomodulatory agents, cytokines, oncolytic viruses, and immune checkpoint inhibitors presents a promising strategy for treating various cancers. This comprehensive review examines the current status and application of CAR-T, CAR-NK, and CAR-M therapies, particularly their integration with immunomodulatory agents and other molecules for treating solid tumors, including glioblastoma, pancreatic, gastric, liver, ovarian, lung, and breast cancers.
MEMBER ACCOUNT
登录成功会直接打开下一页。
